Physician profile
Jason Tu
NPI 1720280852
$1,286.85
in general payments reported to CMS, 2019-2025
18 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.80 · 2020: $33.37 · 2021: $43.35 · 2022: $152 · 2023: $404 · 2024: $241 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.38 | 2022-2025 | Lumigan |
| Horizon Therapeutics Plc | $144.15 | 2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $130.14 | 2022-2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Alcon Vision LLC | $118.65 | 2021-2024 | Clareon |
| Mallinckrodt Hospital Products INC. | $92.91 | 2025 | Acthar |
| Dompe US, INC. | $91.39 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $90.31 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $86.91 | 2022-2025 | Cequa |
| Oyster Point Pharma, INC. | $77.17 | 2022-2024 | Tyrvaya |
| Rxsight INC | $27.08 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $20.50 | 2019 | |
| Bausch & Lomb Americas INC. | $20.02 | 2024 | Miebo, Xiidra |
| Omeros Corporation | $19.94 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $18.79 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $16.51 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.97 | 2020 | |
| Amgen INC. | $13.63 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Tu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.